Pharma BD Deal Intelligence
A bust: Sanofi's $150M upfront for Afrezza bought worldwide rights plus up to $775M in milestones, but weak launch performance forced Sanofi to terminate the alliance in January 2016.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →FierceBiotech's contemporaneous take: the modest $150M upfront 'indicated a lack of interest among the big players,' and Afrezza faced 'heavy skepticism'…
Market feared "MannKind isn't getting enough in the deal when you consider how long and costly the saga of getting Afrezza approved was," plus "a fear that…
STAT framed the termination as confirmation that inhaled insulin remained commercially unviable, with Piper Jaffray's Joshua Schimmer arguing MannKind was…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Sanofi licensed worldwide rights to MannKind's Afrezza inhaled insulin for $150M upfront plus up to $775M in regulatory and sales milestones with profit share. Strategically high-profile but ultimately unsuccessful—Sanofi terminated the alliance in January 2016 amid weak launch performance.
1.5M US cases/yr · $8.0B Sanofi Lantus franchise annual revenue (~$8B at deal time, comparator scale)
Type 1 and Type 2 diabetes are chronic disorders of glucose regulation requiring lifelong glycemic management. Postprandial (mealtime) blood-sugar control with rapid-acting insulin is a core pillar of insulin therapy in both T1D and advanced T2D, and the addressable US insulin-using population at deal time was ~6M patients.
The mealtime insulin market in 2014 was a near-duopoly dominated by Novo Nordisk's NovoLog (insulin aspart) and Eli Lilly's Humalog (insulin lispro), with Sanofi's own Apidra (insulin glulisine) as the distant third injectable. Inhaled insulin had a deeply scarring precedent: Pfizer's Exubera launched 2006 with $2B+ peak-sales projections and was withdrawn within 18 months after $2.8B in writedowns, and Lilly/Novo had abandoned their inhaled programs. Afrezza's clinical pitch was differentiation on speed (peak action ~12-15 min) and avoidance of needles, but the FDA label carried bronchospasm/lung function warnings requiring spirometry baseline testing and excluded patients with COPD/asthma — a meaningful access friction. Sanofi's strategic rationale was to defend its diabetes franchise as Lantus (~$8B/year) faced biosimilar entry, but the FierceBiotech contemporaneous read flagged that the modest $150M upfront 'indicated a lack of interest among the big players' and that Afrezza faced 'heavy skepticism' on commercial potential. The thesis collapsed quickly: Sanofi sold only ~$5.5M in the first nine months of 2015 and ~€7M ($7.7M) total in 2015, terminated the alliance January 2016, and Piper Jaffray's Joshua Schimmer concluded MannKind was 'unlikely to find any takers' for a re-partnership. Afrezza became a textbook case study on inhaled insulin's commercial unviability against entrenched injectable franchises. Source: https://www.statnews.com/pharmalot/2016/01/05/insulin-sanofi-diabetes/
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / MannKind Corporation (this deal) | 2014 | $925M | — |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2014 deals · Sanofi SA deals · Metabolic deals